Chemkart India reported FY26 consolidated revenue of INR 21,482.91 lakhs with 7.1% volume growth despite global supply chain challenges.
The company is constructing a greenfield nutraceutical CDMO facility in JNPT SEZ with advanced technologies like microencapsulation and liposomal delivery systems.
FY26 financial performance showed PAT of INR 2,077.2 lakhs with 9.8% margin, while maintaining strong cash position of INR 3,864.5 lakhs.
Management highlighted strong order pipeline exceeding INR 6,526 lakhs and focus on R&D innovation for future growth in expanding nutraceutical market.